Arcturus Therapeutics Holdings INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Arcturus Therapeutics Reports Progress in mRNA Medicines and Commercialization of KOSTAIVE in 2024
Arcturus Therapeutics transitions to a commercial-stage company with KOSTAIVE sales in Japan and advances its mRNA vaccine and therapeutic pipeline.
NASDAQ
10-K: Arcturus Therapeutics Holdings Inc. Outlines Stock and Insider Trading Policies in 10-K Filing
Arcturus Therapeutics Holdings Inc.'s 10-K filing details stock ownership, insider trading policies, and financial performance, highlighting its focus on mRNA medicines and strategic collaborations.